# CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

> **NCT01454596** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Malignant Glioma
- Glioblastoma
- Brain Cancer
- Gliosarcoma

## Interventions

- **BIOLOGICAL:** Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL
- **DRUG:** Aldesleukin
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01454596
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-16
- **Primary completion:** 2018-11-01
- **Final completion:** 2019-01-17
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01454596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01454596, "CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01454596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*